GeneChem

Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target specific biological pathways in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug, which aims to improve drug tolerability while enhancing therapeutic effects. By releasing its active form specifically in the colon, Giiant's approach allows for targeted treatment at the site of inflammation, potentially preventing the worsening of patients' conditions.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.

SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).

SpecificiT Pharma Inc., a privately held biopharmaceutical company focused on developing innovative personalized cancer immunotherapies. SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with chimeric antigen receptor modified T cells (CAR-T) therapies. SpecificiT’s unique approach is centered on the use of Minor Histocompatability Antigens (“MiHAs”) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.